Compare PCT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | PRCT |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | 157 | N/A |
| Industry | Environmental Services | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | PCT | PRCT |
|---|---|---|
| Price | $8.73 | $27.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.67 | ★ $51.13 |
| AVG Volume (30 Days) | ★ 3.0M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $224,498,000.00 |
| Revenue This Year | N/A | $48.30 |
| Revenue Next Year | $707.73 | $29.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.84 |
| 52 Week Low | $5.40 | $26.23 |
| 52 Week High | $17.37 | $70.80 |
| Indicator | PCT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 39.58 |
| Support Level | $7.71 | N/A |
| Resistance Level | $9.62 | $30.02 |
| Average True Range (ATR) | 0.55 | 1.48 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 30.52 | 29.02 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.